Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4564-4574
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Molecular tumour boards — current and future considerations for precision oncology
Apostolia M. Tsimberidou, Michael Kahle, Henry Hiep Vo, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 843-863
Closed Access | Times Cited: 58
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
Giorgio Bogani, Bradley J. Monk, Matthew A. Powell, et al.
Annals of Oncology (2024) Vol. 35, Iss. 5, pp. 414-428
Closed Access | Times Cited: 36
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Nicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1135-1146
Closed Access | Times Cited: 30
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
M.A. Powell, Line Bjørge, Lyndsay Willmott, et al.
Annals of Oncology (2024) Vol. 35, Iss. 8, pp. 728-738
Open Access | Times Cited: 23
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
Toon Van Gorp, David Cibula, Weiguo Lv, et al.
Annals of Oncology (2024) Vol. 35, Iss. 11, pp. 968-980
Closed Access | Times Cited: 21
The evolving landscape of tissue‐agnostic therapies in precision oncology
Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 5, pp. 433-452
Open Access | Times Cited: 19
Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives
Alyssa Bujnak, Brittany File, Krishnansu S. Tewari
Cancer Management and Research (2025) Vol. Volume 17, pp. 161-170
Open Access | Times Cited: 1
Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors
Ami Jo, Tadahiro Shoji, Haruka Otsuka, et al.
International Journal of Clinical Oncology (2025)
Closed Access
Prognostic and clinical heterogeneity of PD1 and PD-L1- immunohistochemical scores in endometrial cancers
Louisa Proppe, Tobias Jagomast, S Beume, et al.
Archives of Gynecology and Obstetrics (2025)
Open Access
Real-world treatment patterns and clinical outcomes in patients with advanced or recurrent endometrial cancer rechallenged with platinum-based chemotherapy in Europe
Vimalanand S. Prabhu, Sneha S. Kelkar, Jingchuan Zhang, et al.
International Journal of Gynecological Cancer (2025), pp. 101658-101658
Closed Access
POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single‐center cohort
Camilla Nero, Rita Trozzi, Federica Persiani, et al.
Cancer (2025) Vol. 131, Iss. 3
Open Access
WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy
Giovanni Fucá, Cristian Dell'Acqua, Beatrice Peruffo, et al.
Gynecologic Oncology (2025) Vol. 195, pp. 12-15
Closed Access
Practice guideline for management of endometrial cancer in Thailand: a Thai Gynecologic Cancer Society consensus statement
Nicha Assavapokee, Uraiwan Khomphaiboonkij, Siriwan Tangjitgamol, et al.
Journal of Gynecologic Oncology (2025) Vol. 36
Open Access
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access
Implications of the platinum-free interval in endometrial cancer: A legacy worth leaving behind?
Ramez N. Eskander
Gynecologic Oncology (2025) Vol. 194, pp. A3-A4
Closed Access
Refining the Heterogeneity of Mismatch Repair Deficient Endometrial Cancer
Cecilia Prado, Mariana Carvalho Gouveia, Mariana Scaranti
International Journal of Gynecological Cancer (2025), pp. 101830-101830
Closed Access
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer
Juan Francisco Grau-Béjar, E. Yaniz Galende, Qinghe Zeng, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e009143-e009143
Open Access | Times Cited: 4
Endometriumkarzinom – was gibt es Neues?
Laura Weydandt, Lars‐Christian Horn, K Hering, et al.
best practice onkologie (2025)
Closed Access
Comparison of Methods for Testing Mismatch Repair Status in Endometrial Cancer
Marta Mendiola, Victoria Heredia-Soto, Ignacio Ruz‐Caracuel, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14468-14468
Open Access | Times Cited: 9
The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer
Bertha Alejandra Martínez-Cannon, Ilaria Colombo
Cancer Drug Resistance (2024)
Open Access | Times Cited: 3
The Role of Immunotherapy in MMR-Deficient Endometrial Carcinoma: State of the Art and Future Perspectives
Matteo Marchetti, Jacopo Ferrari, Tommaso Vezzaro, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 23, pp. 7041-7041
Open Access | Times Cited: 1
Endometrioid ovarian carcinoma landscape: pathological and molecular characterization
Alexandre de Nonneville, Elsa Kalbacher, Francesco Cannone, et al.
Molecular Oncology (2024)
Open Access | Times Cited: 1
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Matthew A. Powell, David Cibula, David M. O’Malley, et al.
Gynecologic Oncology (2024) Vol. 192, pp. 40-49
Closed Access | Times Cited: 1
Dostarlimab in the 1<sup>st</sup> line treatment of metastatic and recurrent endometrial cancer
Igor Sirák
Onkologie (2024) Vol. 18, Iss. 1, pp. 59-62
Closed Access
Treatment of Metastatic Colorectal Cancer: Beyond Progression
Ali Kaan Güren, Osman Köstek
IntechOpen eBooks (2024)
Open Access
Page 1 - Next Page

Scroll to top